Jan 3, 2018
Sangamo shares surge 3.4% on $12 mln ALS gene therapy c... - https://goo.gl/rRxkPS - #ALS, #Finance, #Gene, #Mln, #Sangamo, #Shares, #Surge, #Therapy
seen from T1
seen from Bangladesh
seen from France
seen from China
seen from Portugal
seen from Malaysia
seen from Japan
seen from Malaysia
seen from Canada
seen from China
seen from Malaysia
seen from Portugal
seen from Malaysia
seen from Kazakhstan
seen from Switzerland
seen from United States
seen from T1
seen from China
seen from Switzerland
seen from China
Sangamo shares surge 3.4% on $12 mln ALS gene therapy c... - https://goo.gl/rRxkPS - #ALS, #Finance, #Gene, #Mln, #Sangamo, #Shares, #Surge, #Therapy
About Sangamo studies, if it works, it means that we will have "Functional Cure", right? So, Can I say that pills will be in the past? (It is so damn hard to travel and live abroad when you depends on the pills. I'm kind stuck in my country. Don't get me wrong, I'm in perfect health because of brazilian public policies, with the free ARVs, but it is frustrating knowing you can't study abroad because in some countries the pills are too expensive or aren't available)
Yes, if the Sangamo approach worked, we could have a functional cure, but that may be a long way off. You should scroll back a week or two and read my recent answer on cure.
In the U.S., if you’re going to be out of the country for a while, you can either get the insurance company to authorize an larger quantity of pills to cover you during your trip, or you can get the pharmacy (or a friend or family member) to ship the medications to you where you are. I don’t know whether that’s possible in Brazil.
Hi Doc, what are your impressions about the method developed by Sangamo BioSciences Inc., which was tested in humans by Calimmune that was approved by FDA recently?
The treatment was not approved by the FDA; the study was approved. Sangamo is working on a process that involves genetically altering CD4 cells so they’re lacking the CCR5 coreceptor, which is required for viral entry by all R5-tropic virus. The modified cells are then expanded and reinfused into the patient, using cyclophosphamide to cause temporary immunosuppression, allowing the modified cells to predominate over the unmodified cells. The idea is to render the patient’s CD4 cells uninfectable, mimicking the cured “Berlin Patient” without the need for a bone marrow transplant.
It’s way to soon to know whether this will work, but there are promising results from early studies.
Gig last night #sangamo #springfieldil #wedding (at Sangamo Club)
"According to Sangamo Biosciences SGMO +4.65% CEO Ed Lanphier, the biotech group’s gene-therapy technology could end up disrupting the broader pharmaceutical market by providing ‘cures’ for diseases caused by certain genetic malfunctions, thereby freeing patients of cumbersome and often expensive drug regimens.
The company’s lead product, a cellular therapy called SB-728, has already shown considerable promise in treating HIV/AIDS. Sangamo is currently running Phase II trials to see if it can help rebuild the immune systems of HIV and AIDS patients, which would conceivably allow them to go off their anti-viral drug regimens. The company plans to unveil preliminary Phase II data during the first half of 2013.
'Our goal is not just to treat but to create a ‘functional cure’ for HIV,” said Lanphier, during a recent interview with MarketWatch.' "